Acadian Asset Management
AXSM icon

Acadian Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Acadian Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$410K Buy
2,427
+1,709
+238% +$295K ﹤0.01% 1410
2025
Q4 		$131K Buy
+718
New +$100K ﹤0.01% 1617
2024
Q4 		– Sell
-2,408
Closed -$216K – 1651
2024
Q3 		$216K Buy
+2,408
New +$210K ﹤0.01% 1336
2016
Q3 		– Sell
-1,909
Closed -$14K – 1412
2016
Q2 		$14K Buy
+1,909
New +$17.6K ﹤0.01% 1163

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management's AXSM Position: Q1 2026 in Review

Acadian Asset Management increased its Axsome Therapeutics (AXSM) stake by 238% in Q1 2026, buying an estimated $295K and bringing the position to 2,427 shares worth $410K. The position accounts for ﹤0.01% of the portfolio, ranked #1410.

Acadian Asset Management first reported a position in AXSM in Q2 2016 and has held it in 4 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Acadian Asset Management held 2,427 shares of Axsome Therapeutics worth $410K as of Q1 2026.
  • Acadian Asset Management bought 1,709 Axsome Therapeutics shares in Q1 2026, an estimated $295K.
  • Axsome Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1410 holding.
  • Acadian Asset Management first reported a position in Axsome Therapeutics in Q2 2016 and has held it in 4 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.